$RDUS News
Last published 1y ago
- 1y agoRDUSRadius Recycling Reports Third Quarter Fiscal 2025 Financial ResultsGlobeNewswireSignificant Improvements Sequentially and Year-Over-Year Higher Ferrous, Nonferrous and Finished Steel Sales Volumes Radius Board Declares Quarterly Dividend PORTLAND, Ore.,
- 1y agoRDUSRadius Recycling Reports Second Quarter Fiscal 2025 Financial ResultsGlobeNewswireFerrous and Finished Steel Sales Volumes Up Year-Over-Year Positive Operating and Free Cash Flow Radius Board Declares Quarterly Dividend PORTLAND, Ore., April 04, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc.
- 1y agoRDUSRADIUS RECYCLING to be Acquired by U.S. Subsidiary of TOYOTA TSUSHO CORPORATION (TTC), Accelerating Investment in Future GrowthGlobeNewswireRadius Recycling Shareholders to Receive $30.00 in Cash Per Share, Delivering Significant Value TTC's Investments to Accelerate Radius Recycling's Growth Strategies and Strengthen Resiliency TTC Committed to
- 1y agoRDUSRadius Recycling Reports First Quarter Fiscal 2025 Financial ResultsGlobeNewswirePORTLAND, Ore., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today reported results for the first quarter of fiscal 2025 ended November 30, 2024. The Company reported a loss per share from
- 1y agoRDUSRadius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific TerritoriesACCESS NewswireBOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. , a specialty biopharmaceutical company focused on
- 1y agoRDUSRadius Recycling Announces First Quarter Fiscal 2025 Earnings Date and Webcast DetailsGlobeNewswirePORTLAND, Ore., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that the Company will report financial results for its first quarter fiscal 2025 ended November 30, 2024 on Wednesday,
- 1y agoRDUSRadius Recycling Publishes Fiscal Year 2024 Sustainability ReportGlobeNewswirePORTLAND, Ore., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Radius Recycling (NASDAQ:RDUS), a global leader in metals recycling, today announced the release of the Company's Fiscal 2024 Sustainability Report. The report
- 1y agoRDUSRadius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and RussiaACCESS NewswireBOSTON, MA / ACCESSWIRE / December 9, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. , a specialty biopharmaceutical company focused
- 2y agoBTURDUSRadius Recycling, Inc. Appoints Marc Hathhorn as Chief Operating OfficerGlobeNewswirePORTLAND, Ore., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today announced the appointment of Marc Hathhorn as Executive Vice President and Chief Operating Officer, effective November 1,
- 2y agoDOWEXPRDUSRadius Recycling, Inc. Appoints Mauro Gregorio to its Board of DirectorsGlobeNewswirePORTLAND, Ore., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that its Board of Directors has appointed Mauro Gregorio, the recently retired President of the Performance Materials
- 2y agoRDUSRadius Recycling, Inc. (RDUS) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDUSRadius Recycling Reports Fourth Quarter and Fiscal 2024 Financial ResultsGlobeNewswireSignificant Sequential Improvement in Operating and Financial Performance in Q4 Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., Oct. 24,
- 2y agoRDUSRadius Recycling Announces Fourth Quarter and Fiscal 2024 Earnings Date and Webcast DetailsGlobeNewswirePORTLAND, Ore., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2024 ended August 31, 2024 on Thursday,
- 2y agoRDUSRadius Recycling, Inc. (RDUS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDUSRadius Recycling Reports Third Quarter Fiscal 2024 Financial ResultsGlobeNewswireFerrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS)
- 2y agoRDUSRadius Recycling Announces Third Quarter Fiscal 2024 Earnings Date and Webcast DetailsGlobeNewswirePORTLAND, Ore., June 18, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that the Company will report financial results for its third quarter fiscal 2024 ended May 31, 2024 on Tuesday, July 2,
- 2y agoRDUSRadius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal DiseasesACCESS NewswireTYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older in this analysis of real-world dataBOSTON, MA /
- 2y agoRDUSRadius Recycling, Inc. (RDUS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDUSRadius Recycling Reports Second Quarter Fiscal 2024 Financial ResultsGlobeNewswireNonferrous and Finished Steel Sales Volumes Up Year-Over-Year Increased Cost Reduction Target by $40 Million Radius Board Declares Quarterly Dividend PORTLAND, Ore., April 04, 2024 (GLOBE NEWSWIRE) --
- 2y agoRDUSSecond Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings DateGlobeNewswireNonferrous and Finished Steel Sales Volumes Up Year-over-Year Cost Reduction Target Increased PORTLAND, Ore., March 14, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today announced preliminary
- 2y agoRDUSRadius Recycling Named One of the 2024 World's Most Ethical CompaniesBusiness WireCompany Honored with Title for Ten Consecutive Years Radius Recycling, Inc. (NASDAQ:RDUS), a global leader in metals recycling, has been recognized as one of the 2024 World's Most Ethical Companies by Ethisphere, a
- 2y agoRDUSSchnitzer Steel Industries, Inc. (RDUS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDUSRadius Recycling Reports First Quarter Fiscal 2024 Financial ResultsBusiness WireFerrous, Nonferrous and Finished Steel Sales Volumes Up Year-Over-Year Radius Board Declares Quarterly Dividend Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ:RDUS) today reported results for the
- 2y agoRDUSRadius Recycling Announces First Quarter Fiscal 2024 Earnings Date and Webcast DetailsBusiness WireSchnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ:RDUS) announced that the Company will report financial results for its first quarter fiscal 2024 ended November 30, 2023 on Thursday, January 4, 2024. The
- 2y agoRDUSRadius Recycling Publishes Fiscal Year 2023 Sustainability ReportBusiness WireSchnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ:RDUS), a global leader in metals recycling, today announced the release of the Company's Fiscal 2023 Sustainability Report, Where Change Begins. The report
- 2y agoRDUSRadius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate ActionBusiness WireToday, TIME named Schnitzer Steel Industries, Inc. dba Radius Recycling's (NASDAQ:RDUS) Chairman and Chief Executive Officer, Tamara Lundgren, to the inaugural TIME100 Climate List, recognizing the 100 most innovative
- 3y agoRDUSRadius Recycling Reports Fourth Quarter and Fiscal 2023 Financial ResultsBusiness WireStrong Operating Cash Flow of $135 Million in the Fourth Quarter Radius Board Declares Quarterly Dividend Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ:RDUS) today reported results for the fourth
- 3y agoRDUSRadius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast DetailsBusiness WireSchnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ:RDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2023 ended August 31, 2023 on Wednesday, October 25, 2023.
- 3y agoRDUSApproval of Tymlos, Nda #208743 (Efficacy)FDA Approved DrugsApproval Date: 12/19/2022; Drug Name: Tymlos, Nda #208743; Active Ingredients: ABALOPARATIDE; Company: Radius Health Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 208743
- 4y agoRDUSGurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.GlobeNewswireCAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Patient Square Capital ("Patient Square") announced today the completion of their acquisition of Radius Health, Inc. (NASDAQ:RDUS) ("Radius"). Radius is a glo
- 4y agoRDUSMenarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast CancerPR NewswireElacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3
- 4y agoRDUSMenarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast CancerBusiness WireElacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal
- 4y agoRDUSVelan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius HealthBusiness WireSale Announcement Follows Successful Velan-Repertoire Campaign Featuring Three World-Class Director Candidates Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, "Velan-Reper
- 4y agoRDUSRadius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant PremiumGlobeNewswireUrges stockholders to vote "FOR" Radius' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) --
- 4y agoRDUSRadius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi SyndromeGlobeNewswireAdvances asset in the neuro-endocrine orphan disease space SCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced 30+ global sites are planned for the seamless Phase 2/3 pivotal trial Primary endpoint of hyperphag
- 4y agoCNVYEPZMOBCIRDUSMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law FirmPR NewswireNEW YORK, July 6, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to share
- 4y agoRDUSVelan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square CapitalBusiness WireVelan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, "Velan-Repertoire" or "we"), collectively one of the largest stockholders of Radius Health, Inc. ("Radius" or the "Company") (
- 4y agoRDUSRadius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square CapitalGlobeNewswireTransaction delivers immediate value and liquidity to Radius shareholders Result of nine-month strategic review process by the Radius Board to maximize shareholder value Potential per share value of $11.00, including $10.00 cash paid at closing and po
- 4y agoRDUSMenarini Group and Radius Health Submit New Drug Application to the U.S. FDA for ElacestrantPR NewswireIntended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and curre
- 4y agoRDUSMenarini Group and Radius Health Submit New Drug Application to the U.S. FDA for ElacestrantGlobeNewswireIntended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and curre
- 4y agoRDUSVelan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to StockholdersBusiness WirePresentation Highlights Lack of Alignment with Stockholders, Poor Corporate Governance, Entrenchment Tactics and Strategic Mismanagement as Reasons Why the Current Board Must Be Meaningfully Reconstituted Letter to Fellow Stockholders Details the Boa
- 4y agoRDUSRubric Capital Management Sends Letter to Radius Health Board of DirectorsBusiness WireOutlines Value Enhancing Initiatives to Address Company's Underperformance and Poor Corporate Governance Intends to Support Velan-Repertoire Director Slate at Upcoming Annual Meeting Rubric Capital Management LP ("Rubric"), an investment advisor
- 4y agoRDUSVelan-Repertoire Responds to Misleading Characterizations by the Radius BoardBusiness WireRadius Touts its "Internal Activism" but the Facts Reveal a Conflicted Board that has Failed to Provide Proper Oversight of CEO Martin or Instill a Culture of Accountability Radius has Experienced a 49% Decline in Stock Price, 60% Employee Turnover a
- 4y agoRDUSRadius Health Expands Non-US Market Footprint for TYMLOSGlobeNewswireGlobalization has been a key priority for the Company over the past two years Three additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries- Pharmbio Korea Inc.: South Korea- Bi
- 4y agoRDUSVelan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual MeetingBusiness WireSends Letter to Fellow Stockholders Detailing the Board's Record of Persistent Value Erosion and Highlights Pathway to Unlock Tremendous Upside Potential Cites Lack of Alignment with Stockholders, Poor Corporate Governance, Entrenchment Tactics and S
- 4y agoRDUSMenarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingPR NewswireSubgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/me
- 4y agoRDUSMenarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireFLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ:RDUS) (collectively, the "Companies") today announced the presentation at the 2022 American Society of Clinical Onc
- 4y agoRDUSRadius Files Definitive Proxy and Mails Letter to StockholdersGlobeNewswireUrges Stockholders to Vote "FOR" Radius' Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company's Significant Progress Since 2
- 4y agoRDUSRadius Health Update on Abaloparatide Transdermal SystemGlobeNewswireCompany ascertained regulatory clarity for possible forward progression of abalo-TDS Additional and successful clinical trial would be required to advance towards an NDA filing New timeline for earliest possible abalo-TDS launch: 2H 2025 Based on reg
- 4y agoRDUSRadius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of DirectorsGlobeNewswireFurther Expands Board's Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced that it has added two new independent memb